Protein changes in peripheral blood samples in the first 24 hours after starting chemotherapy could predict which patients with acute myeloid leukemia respond.
Autologous hematopoietic stem cell transplant is linked to less disability and lower relapse rates than other disease-modifying therapies for patients with secondary progressive multiple sclerosis.
Patients with mantle cell lymphoma (MCL) who survive 2 years without disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population.
Nearly 90% of beta-thalassemia patients were transfusion-free for up to 8 years after treatment with the one-time gene therapy betibeglogene autotemcel (beti-cel), but it costs $2 million.